169 related articles for article (PubMed ID: 15256420)
1. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
Clark JJ; Cools J; Curley DP; Yu JC; Lokker NA; Giese NA; Gilliland DG
Blood; 2004 Nov; 104(9):2867-72. PubMed ID: 15256420
[TBL] [Abstract][Full Text] [Related]
2. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Griswold IJ; Shen LJ; La Rosée P; Demehri S; Heinrich MC; Braziel RM; McGreevey L; Haley AD; Giese N; Druker BJ; Deininger MW
Blood; 2004 Nov; 104(9):2912-8. PubMed ID: 15242881
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
5. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T
Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608
[TBL] [Abstract][Full Text] [Related]
6. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
Walters DK; Stoffregen EP; Heinrich MC; Deininger MW; Druker BJ
Blood; 2005 Apr; 105(7):2952-4. PubMed ID: 15585651
[TBL] [Abstract][Full Text] [Related]
7. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
9. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
[TBL] [Abstract][Full Text] [Related]
10. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.
Barry EV; Clark JJ; Cools J; Roesel J; Gilliland DG
Blood; 2007 Dec; 110(13):4476-9. PubMed ID: 17827387
[TBL] [Abstract][Full Text] [Related]
11. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
12. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
[TBL] [Abstract][Full Text] [Related]
13. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
14. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
16. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
[TBL] [Abstract][Full Text] [Related]
17. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
18. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
19. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R; Miething C; Thiede C; Peschel C; Duyster J
Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
[TBL] [Abstract][Full Text] [Related]
20. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]